IMPORTANCE Biologic therapy (BT) (eg, bevacizumab or cetuximab) is increasingly used to treat metastatic colorectal cancer (mCRC). Recent investigations have suggested that rightor left-sided primary tumor origin affects survival and response to BT.
C olorectal cancers (CRCs) are molecularly heterogeneous with carcinogenic pathways that are, in part, associated with embryologic origin. The right side of the colon, anatomically defined from the cecum through the proximal two-thirds of the transverse colon, develops embryonically from the midgut, whereas the left colon, the distal one-third of transverse colon through the rectum, arises from the hindgut. 1 Increasing evidence demonstrates that rightand left-sided CRCs have distinct genomic patterns owing to genetic and epigenetic alterations. Right-sided tumors have been found to have a higher incidence of mucinous histologic characteristics, 2,3 increased microsatellite instability, 3, 4 and greater frequency of KRAS (OMIM 190070) 5 and BRAF 4, 5 mutations, whereas left-sided CRCs have higher expression of c-myc, 2 RAS, and VEGFA 6 ; amplification of EGFR and ERBB2 (formerly HER2)
5
; and more TP53 gene mutations. 3 Several reports have demonstrated significant differences in survival between right-and left-sided CRCs in nonmetastatic and metastatic settings. [7] [8] [9] [10] In an analysis that com- (mCRC) experienced better overall survival compared with those with right-sided mCRC. Evidence suggests that the association of primary tumor site with the observed outcome differences in mCRC may be attributable in part to differences in response to systemic treatment. 5, 12, 13 Since approval by the US Food and Drug Administration in 2004, biologic therapies (BTs) that target vascular endothelial growth factor (eg, bevacizumab) and epidermal growth factor receptor (EGFR) (eg, cetuximab) have been used in addition to systemic chemotherapy (SC) for treatment of mCRC.
14-18 Recent investigations have confirmed the influence of primary tumor location on the effectiveness of BT. The CALGB/SWOG 80405 (Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer) trial 19 showed that in firstline treatment of mCRC, all patients with wild-type RAS rightsided primary tumors had better survival when treated with bevacizumab compared with cetuximab, whereas patients with left-sided primary tumors had better survival when treated with cetuximab (hazard ratio [HR] , 0.77; 95% CI, 0.59-0.99; P = .04).
Owing to mounting evidence confirming the influence of primary tumor site on response to BT, National Comprehensive Cancer Network (NCCN) recommendations have been revised to include the primary tumor site for first-line treatment of unresectable mCRC. Anti-EGFR therapy with cetuximab or panitumumab is recommended for wild-type RAS and left-sided tumors only. However, the NCCN does not currently recommend stratification by primary tumor site in consideration for subsequent treatment with BT agents.
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Most studies that have evaluated the influence of primary tumor site on response to BT in mCRC are post hoc analyses of large prospective randomized clinical trials or singleinstitution analyses of small patient data sets. We sought to evaluate the association of tumor origin (right or left side) and BT (bevacizumab or cetuximab) with mCRC survival using a large and diverse population-based data set.
Methods
The California Cancer Registry (CCR) is the state-mandated cancer surveillance system 21 In addition to electronically analyzable data fields, CCR data include multiple text fields containing additional treatment information, such as BT type (bevacizumab or cetuximab). The institutional review board of Loma Linda University approved this study and waived the need for informed consent for use of the deidentified CCR data with no patient contact.
Study Design and Population
We performed a population-based nonconcurrent cohort study of statewide California Surveillance Epidemiology and End Results program data assessing the association of 2 BT agents (bevacizumab or cetuximab) with all-cause mortality for rightsided (appendix, cecum, ascending colon, hepatic flexure, or transverse colon) vs left-sided (splenic flexure, descending colon, sigmoid colon, rectosigmoid junction, or rectum) for model building. Age, diagnosis year, and socioeconomic status variables were retained and subsequently used in a logistic regression model to generate a propensity score for treatment probability. In a second step, we used Cox proportional hazard analyses adjusted for propensity score and tumor characteristic to estimate mortality HRs for tumor origin (right or left) and compared SC and bevacizumab or SC and cetuximab vs SC alone. In addition, in the group of patients treated with SC and BT, Cox regression was used to evaluate all-cause mortality HR for the interaction between tumor origin (right or left side) and treatment (SC + bevacizumab or SC + cetuximab). The attributable proportion 28 was used to measure the fraction of excess risk resulting from the interaction between tumor side and BT type. Proportionality assumptions were assessed using the Schoenfield residuals correlation and log-log survival plot. All tests were 2-sided (α = .05) and were performed using SAS software (version 9.4; SAS Institute). These analyes were performed separately for patients with wild-type KRAS mCRC treated with radiation therapy who were diagnosed from January 1, 2010, through December 31, 2014. (Figure 2 ).
When compared with SC alone, treatment with SC plus bevacizumab was associated with decreased mortality for rightsided (n = 1604) (HR, 0.93; 95% CI, 0.88-0.97; P = .02) and leftsided (n = 2683) (HR, 0.88; 95% CI, 0.84-0.91; P < .001) mCRC. However, SC plus cetuximab was associated with decreased mortality only among patients with left-sided mCRC (n = 265) (HR, 0.82; 95% CI, 0.74-0.92; P < .001) ( Table 2) . Patients with right-sided mCRC treated with SC plus cetuximab (n = 125) had significantly higher mortality (HR, 1.31; 95% CI, 1.14-1.51; P < .001) compared those treated with SC alone (Table 2) .
Among all patients receiving SC plus BT, those with rightsided mCRC had higher mortality compared with those with left-sided mCRC treated with SC and bevacizumab (HR, 1.31; 95% CI, 1.25-1.36, P < .001) and SC and cetuximab (HR, 1.88; 95% CI, 1.68-2.12; P < .001). In patients with left-sided mCRC, we found no significant difference in mortality by BT type (HR, 0.97; 95% CI, 0.88-1.05; P = .43). However, patients with rightsided mCRC treated with SC and cetuximab had significantly higher mortality compared with those treated with SC and bevacizumab (HR, 1.43; 95% CI 1.26-1.61; P < .001). Compared with patients with left-sided mCRC treated with SC plus cetuximab, patients with right-sided tumors had a nearly 2-fold higher mortality (HR, 1.93; 95% CI, 1.66-2.25; P < .001). Onethird of the excess risk was attributable to the interaction between tumor site and BT (attributable proportion, 0.33) ( Table 3) . Table 3 also presents findings for subgroup analyses for patients with wild-type KRAS mCRC diagnosed from 2010 through 2014 (n = 668). Those with left-sided wild-type KRAS tumors who received SC plus cetuximab had reduced mortality compared with patients who received SC plus bevacizumab (HR, 0.75; 95% CI, 0.63-0.90; P = .002). In contrast, 
Discussion
We assessed the association of tumor origin and response to treatment with bevacizumab or cetuximab with mortality among patients with mCRC using a large and diverse population-based data set. Our results demonstrated that primary tumor site may be associated with response to BT and survival in mCRC. Patients with right-sided mCRC, regardless of the BT type, showed poorer overall survival compared with patients with left-sided mCRC, highlighting the association of primary tumor location with outcomes in mCRC. We observed a modest improvement in survival among patients with rightand left-sided mCRC with the addition of bevacizumab compared with SC alone. The beneficial influence of bevacizumab in first-line treatment for mCRC has been demonstrated in a phase 3 trial, AVF2107g, in which addition of bevacizumab to irinotecan hydrochloride, fluorouracil, and leucovorin calcium was associated with improved survival among patients with right-and left-sided mCRC. 11 In our study, in patients treated with SC and bevacizumab, primary tumor site had a significant association with outcome, with right-sided mCRC being associated with significantly higher mortality than left-sided mCRC. Other investigators have reported similar outcome differences with bevacizumab treatment for right-and left-sided mCRC.
11,16,29
One of the key observations of our study was the interaction between the primary tumor location and response to cetuximab treatment. Patients with right-sided mCRC who were treated with cetuximab had significantly decreased survival, compared with those treated with SC alone or SC plus bevacizumab despite the relatively small sample size receiving cetuximab. In contrast, patients with left-sided mCRC had improved survival. The observed lack of benefit with cetuximab treatment in right-sided mCRC was further amplified in patients with wild-type KRAS tumors. In contrast, cetuximab was associated with improved survival compared with bevacizumab in patients with wild-type KRAS left-sided mCRC.
Our results are consistent with the findings reported in a recent retrospective analysis of the CALGB/SWOG 80405 trial. tently shown that primary tumor location in the right side is associated with lack of response to anti-EGFR therapy despite wild-type RAS status. In light of this evidence, the NCCN has recently revised its recommendations for the use of anti-EGFR therapy for first-line treatment in mCRC. Treatment with cetuximab or panitumumab is now recommended only for wild-type RAS and left-sided primary tumors. However, stratification by primary tumor location has not been extended to subsequent treatment with BT. 20 In the present study, we found that primary tumor site was associated with response regardless of whether BT agents were used as first-line or a subsequent line of treatment in mCRC. Similar findings were reported in a study by Chen et al, 32 in which the primary tumor site was found to be associated with cetuximab efficacy in thirdline and salvage treatment of wild-type KRAS mCRC. Reasons for survival differences between right-and leftsided mCRC may result from known and unknown genetic factors. Missiaglia et al 5 found higher prevalence of an EGFR inhibitor-sensitive phenotype in left-sided metastatic colon tumors, with right-sided primary tumors characterized by more heterogeneous phenotypes, including poor sensitivity to EGFR inhibitors. Right-sided tumors have also been noted to have more microsatellite instability and BRAF mutations previously associated with poor overall survival. 4 A recent retrospective analysis of tumor samples from patients with CRC treated with cetuximab found that ephrin A2 expression was associated with poorer prognosis, whereas expression of amphiregulin and epiregulin was associated with improved survival. 33 These mechanisms, in addition to other unknown factors, may account, in part, for observed survival differences for BT agents in right-and left-sided mCRC.
Limitations
Our study has several limitations that are inherent to a retrospective analysis of a large population data set. We classified all transverse colon tumors as right sided because current reporting does not distinguish tumors in the proximal twothirds and distal one-third of the transverse colon. Inclusion of distal transverse colon tumors as right sided could have affected our results, although this effect would arguably be minimal given the small proportion of CRC cases in the transverse colon. Furthermore, eliminating transverse colon cases from the analyses did not alter the initial interpretations of findings presented in Table 2 and Table 3 and eTables 1 and 2 in the Supplement. Our study did not allow evaluation of differences in extent of metastatic disease or metastectomy for right-vs leftsided mCRC. Because the extent of metastatic disease and metastectomy is likely to be associated with survival among patients in our study, absence of this information may have confounded our findings and persists as a limitation of our study. Furthermore, CCR data do not include information about duration of therapies that could affect our findings.
Differences in baseline characteristics exist between treatment groups. To minimize these differences, adjustment for propensity score was performed in all multivariable analy- e Referent category is left-sided tumor treated with SC and cetuximab.
f Adjusted for age, diagnosis year, and the part that socioeconomic status played using propensity score.
g For the measure of interaction on additive scale, the attributable proportion was 0.32 (95% CI, 0.14-0.50; P = .01).
Primary ses. Colorectal cancer-specific mortality hazard analyses showed findings similar to those for all-cause mortality, limiting the potential for bias from competing causes of death in the all-cause mortality findings. In addition, our analyses did not distinguish between patients who received oxaliplatin-vs irinotecan-based therapy. Recent data have suggested the potential for interactions between type of SC backbone and BT.
34
These interactions could influence our results. Although KRAS mutation status was not available in the CCR data until 2010, a subgroup analysis confined to patients with wild-type KRAS tumors produced findings similar to those presented in the full analysis. Other molecular markers for mCRC prognosis such as BRAF and microsatellite instability status were unavailable in our study and could have altered our results. Factors that have been shown to affect survival in mCRC, such as the extent of metastatic disease and surgical treatment of metastatic disease, were also not available for analysis.
Conclusions
Despite these limitations, our study results revealed an association of of primary tumor site with response to BT in mCRC. Patients with right-sided mCRC had poorer survival than those with left-sided mCRC regardless of the type of BT and KRAS status. We found that bevacizumab was associated with improved overall survival in right-and left-sided mCRC. However, in wild-type KRAS tumors, use of cetuximab benefited only the patients with left-sided mCRC and was associated with significantly higher mortality among patients with rightsided mCRC. We demonstrated that treatment with cetuximab may be associated with decreased survival among patients with wild-type KRAS right-sided mCRC. Our results have important treatment and health care cost implications. Selection of appropriate BT based on primary tumor site and response may help eliminate ineffective and expensive treatment in patients with mCRC.
To the best of our knowledge, our study is the first US population-based investigation that has validated the findings from clinical trials evaluating the effects of bevacizumab and cetuximab by tumor origin on overall survival in mCRC. This evidence provides further support for translation of clinical trial findings into CRC treatment practice and the need for stratification by primary tumor site in current clinical practice recommendations beyond first-line treatment with BT. Primary tumor site should be routinely incorporated as a stratification factor in future clinical trials to better elucidate potential benefits and harms predicted by tumor origin in mCRC treatment. Further research is needed to define the molecular basis for differences in BT efficacies for right-and leftsided mCRC. Abbreviations: SC, systemic chemotherapy; HR, hazard ratio; CI, confidence interval; BT, biologic therapy; a HR adjusted for age, diagnosis year, mucinous, signet ring, and social economic for part status using propensity score (A) and HR adjusted for age, diagnosis year, and social economic for part status using propensity score (B). b Referent category is right-sided treated with SC and bevacizumab. c Referent category is left-sided treated with SC and bevacizumab. d Referent category is left-sided treated with SC and cetuximab.
